Early or late administration of Nirmatrelvir/ritonavir in mild COVID-19 patients with clinical comorbidities: A propensity score-matched territory-wide study

Early or late administration of Nirmatrelvir/ritonavir in mild COVID-19 patients with clinical comorbidities: A propensity score-matched territory-wide study

Bibliographic Details
Main Authors:	Shuang Liu, Xuan Shen, Fen Zhang, Xiaoqian Shi, Bing Li, Jinfang Xu, Congrong Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Travel Medicine and Infectious Disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S1477893923001163

Similar Items

Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023-10-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
by: Sandra Rajme-López, et al.
Published: (2024-03-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
by: Andrea J. Haddad, et al.
Published: (2024-03-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023-06-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
by: Abraham Ka-chung Wai, et al.
Published: (2023-05-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023-12-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2023-06-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
by: Haein Kim, et al.
Published: (2022-10-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024-01-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01)

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
by: Seth Congdon, et al.
Published: (2023-11-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
by: José Wagner Leonel Tavares-Júnior, et al.
Published: (2023-06-01)

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
by: Elizabeth DeMarco, et al.
Published: (2023-04-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
by: Min Joo Choi, et al.
Published: (2021-01-01)

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
by: Junjun Chen, et al.
Published: (2024-04-01)

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
by: Vasilios Petrakis, et al.
Published: (2023-04-01)

Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.
by: Kathiaja Miranda Souza, et al.
Published: (2023-01-01)

Tacrolimus toxicity in a liver-kidney transplant patient receiving Nirmatrelvir/Ritonavir for COVID-19
by: Santiago F. Galeano Lovera, et al.
Published: (2023-12-01)

Managing nirmatrelvir/ritonavir during COVID-19: pharmacists’ experiences from the Perak state of Malaysia
by: Chee Tao Chang, et al.
Published: (2022-12-01)

Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma
by: Mohamed S. Imam, et al.
Published: (2023-04-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
by: Aili Lu, et al.
Published: (2023-01-01)

A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19
by: Xiujing Zhu, et al.
Published: (2024-01-01)

Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system
by: Deborah E. Malden, et al.
Published: (2024-03-01)

S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY
by: Jon Salmanton-García, et al.
Published: (2023-08-01)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01)